RAMM Pharma Corp. (RAMM.CN)
| Previous Close | 0.0150 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0150 - 0.0150 |
| 52 Week Range | 0.0150 - 0.0950 |
| Volume | |
| Avg. Volume | 11,732 |
| Market Cap | 1.791M |
| Beta (5Y Monthly) | -0.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | Sept 27, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRAMM Pharma Corp. Provides Update on Litigation
Not for Dissemination in the US or through US Newswire Services TORONTO, May 21, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), is providing an update on its dispute with Sergio Martines and NATURALE SCIENCE INC. (together the plaintiffs), the former Chief Executive Officer of Canapar Corp. (“Canapar”) and a former director of the Company as reported in its audited financial statements for the year ended October 31, 2023
GlobeNewswireRAMM Pharma Corp. Announces Corporate Update
Figure 1 Valeriana Officinalis L. (Valerian Root) TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), is pleased to advise its shareholders that in accordance with its previously announced strategy of diversifying its product portfolio, in order to reduce its exposure to the strictly regulated environment of Cannabis-based products, it has launched the formulation and production of a full line of botanical-
